Natco Pharma Ltd
NATCOPHARMBSE 524816PharmaceuticalsMkt cap ₹16,120 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹735 Cr
YoY -44.7%QoQ -0.5%
Net profit · Q1 FY27
₹207 Cr
YoY -57.0%QoQ -23.2%
Net margin · Q1 FY27
28.1%
-8.1 pts vs Q1 FY26
Net profit · FY26
₹1,419 Cr
YoY -24.7%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 735 | 739 | 647 | 1,363 | 1,329 | -44.7% |
| Other income | 59.20 | 77.80 | 58.10 | 100 | 61.70 | -4.1% |
| Total income | 794 | 817 | 705 | 1,463 | 1,391 | -42.9% |
| Profit before tax | 186 | 144 | 161 | 614 | 572 | -67.5% |
| Tax | 63.40 | -89.20 | 20.70 | 95.80 | 91.60 | -30.8% |
| Net profit | 207 | 269 | 151 | 518 | 480 | -57.0% |
| Net margin | 28.1% | 36.4% | 23.4% | 38.0% | 36.1% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 4,078 | 4,430 | 3,999 | 2,707 | 1,945 | -7.9% |
| Other income | 298 | 355 | 128 | 105 | 99.00 | -16.1% |
| Total income | 4,376 | 4,784 | 4,127 | 2,812 | 2,044 | -8.5% |
| Profit before tax | 1,491 | 2,291 | 1,674 | 862 | 202 | -34.9% |
| Tax | 119 | 408 | 285 | 147 | 32.20 | -70.9% |
| Net profit | 1,419 | 1,883 | 1,388 | 715 | 170 | -24.7% |
| Net margin | 34.8% | 42.5% | 34.7% | 26.4% | 8.7% |
BIC's take
We haven't covered Natco Pharma Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:37 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.